Clinical Trial Update: Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating anlotinib hydrochloride in combination with AP for advanced non-squamous non-small-cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)

Snippet

Sponsor: Sichuan University | Conditions: Non-squamous Non-small-cell Lung Cancer, Anlotinib | Phase 1 | Status: COMPLETED | Results posted: 2023-08-03